Luye Pharma Group Ltd
Luye Pharma Group Ltd is a pharmaceutical company engaged in the research, development, production, and sale of generic and branded pharmaceutical products.
Business. Luye Pharma Group Ltd (2186.HK) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The company is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Luye Pharma Group Ltd (2186.HK) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The company is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
Luye Pharma Group Ltd has a basic and diluted share count of 3,994,515,953, indicating no dilution from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability and returns are not available in the current dataset, and no industry_config preferred metrics or cohort medians are provided for comparison. This limits the ability to assess its performance relative to industry benchmarks.
Luye Pharma Group Ltd's revenue concentration and geographic exposure are not disclosed in the available data. The company's segmental breakdown and regional revenue distribution are not provided, making it difficult to evaluate its exposure to specific markets or product lines.
The company's growth trajectory is not quantified in the current dataset. No numeric deltas or revenue history are available to assess its performance over time. Analysts have provided a mean price target of 3.48 CNY, with a median of 3.48 CNY, and a mean recommendation of 2.00 (1=strong buy, 5=strong sell).
The company's risk profile includes low dilution potential and an inability to assess liquidity risk due to missing balance-sheet data. No specific risk factors are detailed in the current dataset, and no dilution sources are identified in the available source documents.
Recent events, including filings and transcripts, are not detailed in the current dataset. No specific disclosures or events are available to inform the company's recent strategic or operational developments.
- Luye Pharma Group Ltd has no dilution from stock options or convertible securities.
- Analysts have assigned a mean price target of 3.48 CNY and a median price target of 3.48 CNY.
- Liquidity risk could not be assessed due to missing balance-sheet data.
- The company's profitability and returns are not available for comparison to industry benchmarks.
- No segmental or geographic revenue breakdown is provided in the current dataset.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥6.31B, +4,1% YoY; Operating income +18,6% YoY.
- ▍Revenue ¥6.31B, +4,1% YoY
- ▍Operating income +18,6% YoY
- ▍Net income +31,1% YoY
- ▍Free cash flow +298,8% YoY
- ▍Net margin 9.8%
Revenue ¥6.06B, −1,3% YoY; Operating income +2,0% YoY.
- ▍Revenue ¥6.06B, −1,3% YoY
- ▍Operating income +2,0% YoY
- ▍Net income −11,4% YoY
- ▍Free cash flow −460,6% YoY
- ▍Net margin 7.8%
Revenue ¥6.14B, +2,7% YoY; Operating income +20,5% YoY.
- ▍Revenue ¥6.14B, +2,7% YoY
- ▍Operating income +20,5% YoY
- ▍Net income −11,9% YoY
- ▍Free cash flow −16,8% YoY
- ▍Net margin 8.7%
Revenue ¥5.98B, +15,0% YoY; Operating income +251,8% YoY.
- ▍Revenue ¥5.98B, +15,0% YoY
- ▍Operating income +251,8% YoY
- ▍Net income +550,0% YoY
- ▍Free cash flow +108,2% YoY
- ▍Net margin 10.1%
Revenue ¥5.20B; Operating income ¥324.2M.
- ▍Revenue ¥5.20B
- ▍Operating income ¥324.2M
- ▍Net margin -2.6%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,18 |
| Revenue | —no estimate | —no estimate | 6,8B CNY |
| Operating income | —no estimate | —no estimate | 1,5B CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Luye Pharma Group Ltd Market data — financials · 2026-05-26
- Luye Pharma Group Ltd Market data — analyst estimates · 2026-05-26
- Luye Pharma Group Ltd Market data — ESG · 2026-05-26
Ownership & reference
Leadership
- Yun Li XueSenior Vice President